MONROVIA, Calif., April 26, 2016 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2016 and provide an update on activities at this year's ASCRS annual meeting on Wednesday, May 11, 2016 after the market close. 

STAAR will host a conference call and webcast on Wednesday, May 11 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress, including activities at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans May 6-10 where the Company will present an overview of post approval ICL data available for the first time and rebranding aimed at building the visual freedom market for the Company's implantable lenses. To access the conference call (Conference ID 83736865), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 83736865) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.

Also, as previously disclosed, on February 11, 2016, one of the Company's shareholders increased its beneficial ownership of the Company's common stock to approximately 26% of all shares outstanding. This level of ownership constituted a "Change in Control" under the Company's Amended and Restated 2003 Omnibus Equity Incentive Plan ("Plan").  As a result all unvested equity awards outstanding under the Plan immediately vested and the Company recorded an aggregate $6.9 million non-cash expense in the first quarter of 2016.

About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL". More than 550,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 360 employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.
 

 
 
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/staar-surgical-to-report-first-quarter-results-on-may-11-2016-300257693.html
SOURCE STAAR Surgical Company